Get Constitutive Ogg1 Variant Together With Brca Mutations Display Accelerated Telomere Shortening 2020-2025

BRCA1 and BRCA2 are two different genes that help suppress tumors. The primary difference is their location and specific roles in DNA repair. Mutations in either gene can elevate the risk of developing certain cancers, and they can present unique profiles in how they influence overall health. Awareness of both is important, particularly when considering conditions like the constitutive OGG1 variant together with BRCA mutations display accelerated telomere shortening.

The genes most commonly affected in hereditary breast and ovarian cancer are the breast cancer 1 (BRCA1) and breast cancer 2 (BRCA2) genes. About 3% of breast cancers (about 7,500 women per year) and 10% of ovarian cancers (about 2,000 women per year) result from inherited mutations in the BRCA1 and BRCA2 genes.

In view of histological types, approximately 75% of BRCA1 pathogenic variant breast cancers are invasive ductal carcinomas, and 10% are atypical medullary cancers. In BRCA2 pathogenic variant breast cancer, lobular or ductal with lobular types are more frequent (in up to 10% of cases) [25].

BRCA1 and BRCA2: The most common cause of hereditary breast cancer is an inherited mutation in the BRCA1 or BRCA2 gene. In normal cells, these genes help make proteins that repair damaged DNA. Mutated versions of these genes can lead to abnormal cell growth, which can lead to cancer.

BRCA mutations increase the risk of a number of cancers such as prostate cancer and pancreatic cancer, not to mention the increased risk of breast cancer in men. Lynch syndrome increases the lifetime risk of a number of cancers, including colorectal cancer, stomach cancer, kidney cancer and pancreatic cancer.

Inheriting damaged copies of the BRCA1 or BRCA2 genes can increase the risk for breast cancer and ovarian cancer in women and the risk for breast and prostate cancer in men, as well as other cancers.

Background. Most BRCA1 or BRCA2 mutation carriers have inherited a single (heterozygous) mutation. Transheterozygotes (TH) who have inherited deleterious mutations in both BRCA1 and BRCA2 are rare, and the consequences of transheterozygosity are poorly understood.

BRCA1- and BRCA2-associated hereditary breast and ovarian cancer (HBOC) is characterized by an increased risk for male and female breast cancer, ovarian cancer (including fallopian tube and primary peritoneal cancers), and to a lesser extent other cancers such as prostate, pancreatic, and melanoma, primarily in ...